Biotech executives and a handful of teachers pleaded with U.S. and European regulators on Thursday to undertake new requirements for approving antibody medicine in opposition to Covid, significantly for immunocompromised and different susceptible sufferers.
The four-hour listening to got here as companies, corporations, and researchers face a basic mismatch: The virus is evolving quicker than our potential to develop interventions below regular — and even regular emergency — procedures.
Proceed to STAT+ to learn the complete story…
